SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project with an active developer, attracting attention from investors looking to move beyond typical pump-and-dump cycles. The community is actively pushing for mainstream platform visibility and increased trading volume to support their long-term goal of hitting significant market cap milestones.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum and trending as investors react to a strategic payroll infrastructure partnership with Stellar, fueling optimism for broader institutional adoption. The community is actively discussing the potential for future XRP collaboration and a possible Coinbase listing, with many using the current price consolidation as a strategic accumulation phase.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing heightened investor interest driven by a combination of its ongoing strategic pivot into pharmaceutical manufacturing, a fortified balance sheet, and market speculation regarding potential domestic supply chain contracts. Community discussion remains heavily focused on the company's turnaround progress, its status as a potential beneficiary of new pharmaceutical import tariffs, and bullish long-term value projections based on its infrastructure and asset base.

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Grace Therapeutics is gaining momentum as investors anticipate the upcoming PDUFA date for its drug candidate GTx-104. The community is focused on the potential for institutional accumulation and the stock's low float, with many discussing the strategic value of the asset as the company nears its regulatory catalyst.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened social media activity and trading volume driven by investor interest in its post-quantum cryptography features and recent institutional developments, including a shift toward US-based operations. The community remains deeply divided, with long-term holders expressing conviction in the project's technology and future adoption, while active traders continue to debate its recent price volatility and past performance relative to broader market trends.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is currently drawing significant attention as investors shift toward defensive, high-quality dividend compounders amid broader market volatility. The community is actively debating whether the stock's current price levels represent a strategic accumulation point for long-term wealth building or a potential value trap as the company navigates ongoing cost-savings initiatives.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and active call buying as the community debates potential short-squeeze dynamics and the impact of a high short interest against an anticipated operational turnaround. Traders are closely monitoring the stock's price action around critical technical levels, fueled by speculation regarding activist interest and upcoming earnings, while opinions remain sharply divided on the company's long-term sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>New Street analyst Pierre Ferragu upgraded Arm to ‘Buy’ from ‘Neutral’ with a $145 price target, representing an upside of about 28.6% compared to current trading levels of $112.78 at the time of writing.&nbsp;</li><li>Ferragu said that Arm reported a 4% royalty beat in fiscal Q3 and that is what really matters, the analyst told investors, according to TheFly.&nbsp;</li><li>RBC Capital analyst Srini Pajjuri cut the company’s price target to $130 from $140 while maintaining an ‘Outperform’ rating on the shares.</li></ul>Arm Holdings Plc. (ARM) stock was in the spotlight on Thursday as the company received attention from Wall Street analysts after posting third-quarter (Q3) 2025 earnings on Wednesday.New Street, RBC Capital, Bank of America, and Mizuho were among analysts who revised their outlook and price targets on the firm.Shares of ARM gained over 7% on Thursday at the time of writing.<h2 class="st-heading-2">Street Consensus</h2>New Street analyst Pierre Ferragu upgraded Arm to ‘Buy’ from ‘Neutral’ with a $145 price target, representing an upside of about 28.6% compared to current trading levels of $112.78 at the time of writing.Ferragu said that Arm reported a 4% royalty beat in fiscal Q3 and that is "what really matters," the analyst told investors, according to TheFly. The analyst added that market fears of a weak 2026 for smartphones are "overdone" as the premium segment is unaffected, adding that the post-earnings pullback reflects temporary concerns about smartphones and creates an entry point, while the company’s datacenter segment will contribute meaningfully to growth.Meanwhile, RBC Capital analyst Srini Pajjuri cut the company’s price target to $130 from $140 while maintaining an ‘Outperform’ rating on the shares, as per TheFly. The analyst cited a slower Q4 royalty growth outlook, even though the management sounded confident about sustaining 20% growth in FY27, the analyst said in a research note, as per TheFly.BofA lowered Arm’s price target to $115 from $120 and maintained a ‘Neutral’ rating on the shares, citing the company’s results that showed in-line to modestly better-than-expected Q3 results and Q4 guidance.Mizuho also lowered the firm's price target to $160 from $190 and kept an ‘Outperform’ rating on the shares. The analyst said that it views Arm's growth as solid, and recommended buying the post-earnings pullback in the company’s shares.<h2 class="st-heading-2">Earnings Update</h2>Arm posted a 26% year-on-year growth in quarterly revenues, clocking $1.24 billion in Q3 2025, and beating street expectations of $1.23 billion. The company said that its royalty revenue increased 27% year-over-year due to growth across its target end markets such as artificial intelligence, data centers, smartphones, physical AI, and edge AI.The company reported adjusted profit of $0.43 per share, beating street consensus of $0.41 per share.Providing forward guidance, Arm said it expects Q4 revenues to come between $1.42 billion and $1.52 billion, compared to street expectations of about $1.44 billion on average.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARM">ARM shares</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours. Meanwhile, message volumes increased from ‘high’ to ‘extremely high’ levels.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_06_at_12_52_03_AM_png_3fc09073b9.webp" alt="Screenshot 2026-02-06 at 12.52.03 AM.png" width="1276" height="154"></figure>&nbsp;One bullish user said the company has value and reaches the world’s devices.<stembedurl>https://stocktwits.com/jjg111/message/644155887</stembedurl>&nbsp;Shares of ARM have declined by over 34% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-flags-wording-methodology-updates-in-google-parent-alphabet-fresh-filing/cZbZQNwR4VU">Michael Burry Flags Wording, Methodology Updates In Google Parent Alphabet’s Fresh Filing</a>

In this photo illustration, the logo of Arm Holdings plc is displayed on a smartphone screen, with a stock market chart in the background.

ARM Shares Garner Street Attention After Q3 Earnings — What’s The Consensus?

New Street, RBC Capital, Bank of America, and Mizuho were among analysts who revised their outlook and price targets on Arm Holdings after it posted third-quarter (Q3) 2025 earnings on Wednesday. 

Equity

<ul class="summary-bullets"><li>Arm’s third quarter revenue grew 26% year-on-year to $1.24 billion, representing record quarterly revenue.</li><li>The company said it expects Q4 revenue in the range of $1.42 billion to $1.52 billion, analysts on average are expecting the revenue of $1.44 billion.&nbsp;</li><li>Arm in its earnings call said that SoftBank is "not interested" in selling any shares of Arm stock.</li></ul>Shares of Arm Holdings fell more than 8% in extended hours of trading on Wednesday as investors were spooked by higher operating expenses.The company posted $716 million in adjusted operating expenses during the quarter, a 37% rise from a year-ago quarter.Arm in its earnings call said that SoftBank (SFTBY) is "not interested" in selling any shares of Arm stock.<h2 class="st-heading-2">Strong Quarter</h2>Arm’s third quarter revenue grew 26% year-on-year to $1.24 billion, representing record quarterly revenue and its fourth consecutive billion dollar revenue quarter. Analysts on average were expecting revenue of $1.23 billion.&nbsp;It said its royalty revenue grew a robust 27% year-over-year to a record of $737 million driven by growth across our target end markets, including AI and general purpose data center, smartphones, physical AI and edge AI.&nbsp;“Arm delivered a record revenue quarter as demand for AI computing on our platform continues to accelerate” said Rene Haas, CEO. “Record royalty results in the third quarter reflect the growing scale of our ecosystem, as customers design the Arm compute platform into next-generation systems across cloud, edge, and physical environments to deliver high-performance, power-efficient AI. The fundamentals of the Arm business have never been stronger.”It reported adjusted profit of $0.43 per share compared with $0.39 in the same period a year ago, analysts on average had expected profit of $0.41 per share.<h2 class="st-heading-2">Outlook</h2>The company said it expects Q4 revenue in the range of $1.42 billion to $1.52 billion, analysts on average are expecting the revenue of $1.44 billion.&nbsp;Arm sees Q4 profit in between $0.54 to $0.52 per share, analysts’ consensus for the fourth quarter is $0.56 per share. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ARM trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One bullish user said that “ARM will see Nvidia 2022-2024 like growth in coming years, staying the course here”.<stembedurl>https://stocktwits.com/KryptonResearch/message/644033275</stembedurl>Another user predicted that the stock will be at least $125 by the end of the month.<stembedurl>https://stocktwits.com/DragonMk/message/644030008</stembedurl>Another user called the stock “oversold”.<stembedurl>https://stocktwits.com/Dvb3445/message/644029171</stembedurl> &nbsp;

The replica of the ARM is an electronic chip board during a collaborative ceremony launching a partnership between Malaysia and ARM Holdings in Kuala Lumpur, Malaysia, on March 5, 2025. 

Why Is Arm Stock Falling 8% After Hours? 

Higher adjusted operating expenses in its third quarter spooked investors. 

Shares of Quest Diagnostics, Inc. jumped nearly 6% to hit levels last seen toward the end of November, driven by upbeat quarterly earnings.The stock is on course to notch its best intraday session in over three months.The company reported fourth-quarter (Q4) adjusted earnings per share (EPS) of $2.23, beating the consensus estimate of $2.18, while revenue came in at $2.62 billion, surpassing expectations of $2.58 billion."In the fourth quarter, we delivered impressive revenue growth of nearly 15%, including approximately 5% organic growth, while also improving our profitability," said CEO Jim Davis.He added that Quest completed eight acquisitions in 2024, including LifeLabs in Canada, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers.Looking ahead, Quest sees full-year adjusted EPS between $9.55 and $9.80, compared to the consensus estimate of $9.72.&nbsp;The company expects FY25 revenue in the range of $10.7 billion to $10.85 billion, above the consensus of $10.67 billion.&nbsp;It also anticipates generating $1.45 billion in cash from operations and plans capital expenditures of $500 million for the year.Quest’s board of directors has authorized a 6.7% increase in its quarterly dividend from $0.75 to $0.80 per share, or $3.20 annually, effective with the dividend payable on April 21 to shareholders of record on April 7.&nbsp;The company said it has raised its dividend annually since 2011.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DGX_sentiment_and_message_volume_Jan_30_cbb46c7261.png" alt="DGX sentiment and message volume Jan 30.png" width="1318" height="324"><figcaption>DGX sentiment and message volume Jan 30 as of 12:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Quest turned ‘extremely bullish,’ with message volume soaring.<stembedurl>https://stocktwits.com/GettnFibbywIT/message/602106527</stembedurl>The stock has generated significant attention on the platform, with message volume tripling over the past three months.&nbsp;<a href="https://stocktwits.com/symbol/DGX">Quest</a> rose to prominence during the COVID-19 pandemic, supplying virus testing kits at scale. As infections waned, the company pivoted back to its core business.&nbsp;Last year, it struck a deal to acquire LifeLabs, a leading Canadian community laboratory services provider, from pension fund OMERS for approximately C$1.35 billion ($985 million), including net debt.Shares of Quest have gained more than 26% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Quest Diagnostics logo of a US clinical laboratory is displayed on a smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Quest Diagnostics Stock Hits Over 2-Month High On Q4 Beat, Dividend Hike: Retail Cheer Grows

Quest completed eight acquisitions in 2024, including LifeLabs, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers.

Absolute Shares Trust - WBI BullBear Yield 3000 ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

WBIG
WBI Investments Inc - WBI BullBear Yield 3000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest WBIG News

WBIGWBI Investments Inc - WBI BullBear Yield 3000 ETF